Overview Dividends

(CHE) Chemed - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US16359R1032

Hospice, Palliative, Plumbing, Drain, Restoration

CHE EPS (Earnings per Share)

EPS Growth (3Y CAGR): -0.82%
EPS Trend (3Y Correlation): 7.1%

CHE Revenue

Revenue Growth (3Y CAGR): 4.98%
Revenue Trend (3Y Correlation): 93.0%

Description: CHE Chemed November 06, 2025

Chemed Corp (NYSE:CHE) operates a dual-business model: the VITAS segment delivers hospice and palliative-care services across the U.S., while the Roto-Rooter segment provides residential and commercial plumbing, drain cleaning, excavation, and water-restoration services through company-owned locations, franchisees, and independent contractors.

Key metrics to watch: VITAS generated roughly $4.6 bn in revenue in FY 2023, with an EBITDA margin near 12 %, reflecting stable Medicare-reimbursement rates; the Roto-Rooter segment contributed about $2.2 bn, benefitting from a 3-4 % annual growth in U.S. residential construction and aging-in-place plumbing replacement cycles. A material driver for the hospice side is the U.S. aging population-people aged 65+ are projected to rise from 54 million in 2023 to 73 million by 2035, expanding the addressable market.

Given the blend of recession-resilient healthcare cash flows and a cyclical, but demand-steady, plumbing franchise business, CHE’s valuation hinges on how well it can cross-sell services and manage regulatory risk in hospice reimbursement.

For a deeper, data-driven assessment of CHE’s risk-adjusted upside, you might explore the analyst tools on ValueRay to see how its forward-looking metrics compare to sector peers.

CHE Stock Overview

Market Cap in USD	6,285m
Sub-Industry	Health Care Services
IPO / Inception	1973-05-03

CHE Stock Ratings

Growth Rating	-25.1%
Fundamental	86.8%
Dividend Rating	55.1%
Return 12m vs S&P 500	-31.0%
Analyst Rating	4.67 of 5

CHE Dividends

Dividend Yield 12m	0.48%
Yield on Cost 5y	0.45%
Annual Growth 5y	8.06%
Payout Consistency	96.0%
Payout Ratio	9.6%

CHE Growth Ratios

Growth Correlation 3m	-59.6%
Growth Correlation 12m	-63.2%
Growth Correlation 5y	47%
CAGR 5y	-3.66%
CAGR/Max DD 3y (Calmar Ratio)	-0.10
CAGR/Mean DD 3y (Pain Ratio)	-0.34
Sharpe Ratio 12m	0.51
Alpha	-28.17
Beta	0.429
Volatility	24.45%
Current Volume	141.5k
Average Volume 20d	168.9k
Stop Loss	421.5 (-3%)
Signal	-0.62

Piotroski VR‑10 (Strict, 0-10) 8.5

Net Income (278.8m TTM) > 0 and > 6% of Revenue (6% = 151.8m TTM)

FCFTA 0.22 (>2.0%) and ΔFCFTA 4.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 4.08% (prev 9.49%; Δ -5.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.26 (>3.0%) and CFO 419.7m > Net Income 278.8m (YES >=105%, WARN >=100%)

Net Debt (11.7m) to EBITDA (436.5m) ratio: 0.03 <= 3.0 (WARN <= 3.5)

Current Ratio 1.35 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (14.5m) change vs 12m ago -3.63% (target <= -2.0% for YES)

Gross Margin 32.24% (prev 33.68%; Δ -1.44pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 149.2% (prev 134.3%; Δ 14.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 113.7 (EBITDA TTM 436.5m / Interest Expense TTM 3.27m) >= 6 (WARN >= 3)

Altman Z'' 13.31

(A) 0.06 = (Total Current Assets 395.2m - Total Current Liabilities 292.0m) / Total Assets 1.62b

(B) 1.78 = Retained Earnings (Balance) 2.89b / Total Assets 1.62b

warn (B) unusual magnitude: 1.78 — check mapping/units

(D) 5.35 = Book Value of Equity 2.93b / Total Liabilities 546.9m

Total Rating: 13.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 86.78

1. Piotroski 8.50pt = 3.50

2. FCF Yield 5.72% = 2.86

3. FCF Margin 14.24% = 3.56

4. Debt/Equity 0.13 = 2.49

5. Debt/Ebitda 0.03 = 2.50

6. ROIC - WACC (= 17.08)% = 12.50

7. RoE 24.37% = 2.03

8. Rev. Trend 92.99% = 6.97

9. EPS Trend 7.13% = 0.36

What is the price of CHE shares?

As of November 08, 2025, the stock is trading at USD 434.61 with a total of 141,521 shares traded.
Over the past week, the price has changed by +0.77%, over one month by -0.34%, over three months by +0.07% and over the past year by -21.33%.

Is Chemed a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Chemed (NYSE:CHE) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 86.78 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CHE is around 379.50 USD . This means that CHE is currently overvalued and has a potential downside of -12.68%.

Is CHE a buy, sell or hold?

Chemed has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy CHE.

Strong Buy: 2
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CHE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	578.5	33.1%
Analysts Target Price	578.5	33.1%
ValueRay Target Price	419.2	-3.5%

CHE Fundamental Data Overview November 02, 2025

Market Cap USD = 6.28b (6.28b USD * 1.0 USD.USD)
P/E Trailing = 22.8201
P/E Forward = 17.6056
P/S = 2.4835
P/B = 5.3745
P/EG = 1.7594
Beta = 0.429
Revenue TTM = 2.53b USD
EBIT TTM = 372.2m USD
EBITDA TTM = 436.5m USD
Long Term Debt = 140.8m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 42.0m USD (from shortTermDebt, last quarter)
Debt = 141.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.7m USD (from netDebt column, last quarter)
Enterprise Value = 6.30b USD (6.28b + Debt 141.5m - CCE 129.8m)
Interest Coverage Ratio = 113.7 (Ebit TTM 372.2m / Interest Expense TTM 3.27m)
FCF Yield = 5.72% (FCF TTM 360.4m / Enterprise Value 6.30b)
FCF Margin = 14.24% (FCF TTM 360.4m / Revenue TTM 2.53b)
Net Margin = 11.02% (Net Income TTM 278.8m / Revenue TTM 2.53b)
Gross Margin = 32.24% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.71b) / Revenue TTM)
Gross Margin QoQ = 28.91% (prev 29.85%)
Tobins Q-Ratio = 3.88 (Enterprise Value 6.30b / Total Assets 1.62b)
Interest Expense / Debt = 1.41% (Interest Expense 2.00m / Debt 141.5m)
Taxrate = 23.11% (19.3m / 83.5m)
NOPAT = 286.2m (EBIT 372.2m * (1 - 23.11%))
Current Ratio = 1.35 (Total Current Assets 395.2m / Total Current Liabilities 292.0m)
Debt / Equity = 0.13 (Debt 141.5m / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = 0.03 (Net Debt 11.7m / EBITDA 436.5m)
Debt / FCF = 0.03 (Net Debt 11.7m / FCF TTM 360.4m)
Total Stockholder Equity = 1.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.17% (Net Income 278.8m / Total Assets 1.62b)
RoE = 24.37% (Net Income TTM 278.8m / Total Stockholder Equity 1.14b)
RoCE = 28.97% (EBIT 372.2m / Capital Employed (Equity 1.14b + L.T.Debt 140.8m))
RoIC = 24.53% (NOPAT 286.2m / Invested Capital 1.17b)
WACC = 7.46% (E(6.28b)/V(6.43b) * Re(7.60%) + D(141.5m)/V(6.43b) * Rd(1.41%) * (1-Tc(0.23)))
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.44%
[DCF Debug] Terminal Value 79.65% ; FCFE base≈341.3m ; Y1≈376.4m ; Y5≈485.5m
Fair Price DCF = 579.4 (DCF Value 8.44b / Shares Outstanding 14.6m; 5y FCF grow 11.79% → 3.0% )
EPS Correlation: 7.13 | EPS CAGR: -0.82% | SUE: -0.15 | # QB: 0
Revenue Correlation: 92.99 | Revenue CAGR: 4.98% | SUE: -0.14 | # QB: 0

Additional Sources for CHE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle